Search Result
Results for "
Model antigen
" in MedChemExpress (MCE) Product Catalog:
62
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-161549
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Phosphotyrosine/BSA is an antigen-adjuvant conjugate formed by coupling Phosphotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161553
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Biotin/KLH is an antigen-adjuvant conjugate that consists of Biotin and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161561
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
PROMETON/OVA is an antigen-adjuvant conjugate formed by the coupling of PROMETON and ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and enhances cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-161583
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Marijuana/BSA is the antigen-adjuvant conjugate of Marijuana and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-161562
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
PROMETON/BSA is an antigen-adjuvant conjugate formed by the coupling of PROMETON with bovine serum albumin (BSA). By coupling the antigen to the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-161529
-
|
|
Angiotensin Receptor
|
Inflammation/Immunology
|
|
Angiotensin I/BSA is an antigen-adjuvant conjugate of Angiotensin I and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-163556
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
COT/BSA is the antigen-adjuvant conjugate of COT (cyclooctatetraene) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161558
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Ractopamine/KLH is an antigen-adjuvant conjugate of Ractopamine (HY-113781) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-161533
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Digoxin/BSA is an antigen-adjuvant conjugate of Digoxin (HY-B1049) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161542
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Isoniazid/BSA is an antigen-adjuvant conjugate of Isoniazid (HY-B0329) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161540
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Oxytetracycline/OVA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, it enhances the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or destroy the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-163555
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
BZO/BSA is an antigen-adjuvant conjugate formed by the coupling of BZO (benzodiazepine) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-161555
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Clenbuterol/KLH is an antigen-adjuvant conjugate of Clenbuterol (HY-B1615) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161554
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Clenbuterol/BSA is an antigen-adjuvant conjugate of Clenbuterol (HY-B1615) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161566
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
DHT/BSA is an antigen-adjuvant conjugate formed by the coupling of DHT (dihydrotestosterone) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161532
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Eugenol/OVA is an antigen-adjuvant conjugate formed by the conjugation of Eugenol (HY-N0337) with Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161591
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
SEM/BSA is an antigen-adjuvant conjugate formed by the conjugation of SEM (furanesalin) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161594
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Furazolidone/BSA is the antigen-adjuvant conjugate of Furazolidone (HY-B1336) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161530
-
|
|
Angiotensin Receptor
|
Inflammation/Immunology
|
|
Angiotensin II/BSA is an antigen-adjuvant conjugate formed by the coupling of Angiotensin II with bovine serum albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-163553
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Metronidazole/BSA is an antigen-adjuvant conjugate of Metronidazole (HY-B0318) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-161557
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Ractopamine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Ractopamine (HY-113781) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161590
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
AHD/BSA is the antigen-adjuvant conjugate of AHD (furan-2-carboxylic acid) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy the main epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161586
-
-
-
- HY-161546
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Melamine/KLH is an antigen-adjuvant conjugate formed by coupling Melamine (HY-Y1117) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161547
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Tetracycline/BSA is an antigen-adjuvant conjugate formed by the conjugation of Tetracycline (HY-A0107) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161535
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Oxytetracycline/BSA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-161580
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
3-Nitrotyrosine/BSA is an antigen-adjuvant conjugate formed by the conjugation of 3-Nitrotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161528
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
T3/OVA is an antigen-adjuvant conjugate formed by conjugating T3 (thyroxine) with ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161560
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Tacrolimus/BSA is the antigen-adjuvant conjugate formed by the conjugation of Tacrolimus (HY-13756) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161541
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Estradiol/BSA is the antigen-adjuvant conjugate formed by the coupling of Estradiol (HY-B0141) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161589
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
GABA/KLH is an antigen-adjuvant conjugate formed by the coupling of GABA (γ-aminobutyric acid) with keyhole limpet hemocyanin (KLH). By coupling the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161534
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Sulfadiazine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Sulfadiazine (HY-B0273) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161552
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
T3/BSA is an antigen-adjuvant conjugate of T3 (thyroid hormone) and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161588
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
GABA/BSA is an antigen-adjuvant conjugate formed by the coupling of GABA (γ-aminobutyric acid) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161559
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Sudan I/OVA is an antigen-adjuvant conjugate formed by coupling Sudan I (HY-D0024) with Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the main epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161585
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Diethylstilbestrol/KLH is an antigen-adjuvant conjugate formed by the coupling of Diethylstilbestrol (HY-14598) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-P10994
-
|
Eps8(327-335)
|
EGFR
IFNAR
Interleukin Related
TNF Receptor
Complement System
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .
|
-
-
- HY-161544
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Cholyglycine/BSA is a conjugate of Cholyglycine and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-161545
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Sudan I/BSA is the antigen-adjuvant conjugate formed by Sudan I (HY-D0024) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161556
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Alginic acid/KLH is an antigen-adjuvant conjugate formed by the coupling of Alginic acid (HY-W127758) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161526
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
T3/KLH is an antigen-adjuvant conjugate formed by the coupling of T3 (thyroid hormone) with keyhole limpet hemocyanin (KLH). By coupling the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161584
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Sudan I/KLH is an antigen-adjuvant conjugate formed by the coupling of Sudan I (HY-D0024) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161543
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
DHT/KLH is a conjugate of DHT (dihydrotestosterone) and keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt linear epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161587
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Chloramphenicol/OVA is a conjugate of Chloramphenicol (HY-B0239) and Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-161581
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Metronidazole/OVA is a conjugate of Metronidazole (HY-B0318) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161565
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Gastrin(1-17)/BSA is an antigen-adjuvant conjugate formed by the coupling of Gastrin(1-17) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-163552
-
|
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Prostaglandin F2a/BSA is an antigen-adjuvant conjugate formed by the conjugation of Prostaglandin F2a with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation as well as the generation of antigen-specific T cells.
|
-
-
- HY-161563
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
4,4'-Sulfonyldiphenol/BSA is the antigen-adjuvant conjugate of 4,4'-Sulfonyldiphenol (HY-W011927) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
-
- HY-161548
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Metronidazole/KLH is a conjugate of Metronidazole (HY-B0318) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
-
- HY-161531
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
Diethylstilbestrol/BSA is a conjugate of Diethylstilbestrol (HY-14598) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-163550
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
5-MethylCytosine/BSA is a conjugate of 5-MethylCytosine (HY-W008091) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161551
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
25-OH Vitamin D3/KLH is an antigen-adjuvant conjugate of 25-OH Vitamin D3 (HY-158285) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-155176
-
|
|
HDAC
|
Cancer
|
|
SP-2-225 is a selective HDAC6 inhibitor. SP-2-225 enhance the production of cancer-associated antigens and macrophage antigen cross-presentation to T cells. SP-2-225 reduces the tumor volume in a syngeneic SM1 melanoma model .
|
-
- HY-NP141
-
|
4-Hydroxy-3-nitrophenylacetyl-bovine serum albumin
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
NP-BSA (4-Hydroxy-3-nitrophenylacetyl-bovine serum albumin) is an antigen-adjuvant conjugate of 4-Hydroxy-3-nitrophenylacetyl (NP) conjugated to bovine serum albumin (BSA), which is an immune complex. By conjugating antigens to protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the generation of antigen-specific T cells .
|
-
- HY-161525
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid linker/BSA is the conjugate of 1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid linker and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, it enhances the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-P1571
-
|
NP 396
|
Arenavirus
|
Inflammation/Immunology
|
|
Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .
|
-
- HY-P1571A
-
|
NP 396 TFA
|
Arenavirus
|
Inflammation/Immunology
|
|
Nucleoprotein (396-404) TFA is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) TFA is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .
|
-
- HY-105999
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
APC 366 is a selective inhibitor of mast cell tryptase (Ki=7.1 μM). APC 366 inhibits antigen-induced early asthmatic response (EAR), late asthmatic response (LAR), and bronchial hyperresponsiveness (BHR) in a sheep model of allergic asthma .
|
-
- HY-153808
-
|
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
|
Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response .
|
-
- HY-163760
-
|
|
HuR
MMP
|
Cancer
|
|
ZM-32 is an inhibitor for human antigen R (HuR), that downregulates the expression of VEGF-A and MMP9, and thus inhibits breast cancer tumor angiogenesis. ZM-32 exhibits broad-spectrum anti-proliferative effects in a variety of cancer cell lines, and exhibits antitumor efficacy against MDA-MB-231 in mouse models .
|
-
- HY-P9932
-
|
ETI 204
|
Bacterial
|
Infection
Cardiovascular Disease
|
|
Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
|
-
- HY-163768
-
|
|
β-catenin
|
Inflammation/Immunology
Cancer
|
|
Antitumor agent-172 (Compound 28) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 3.92 μM. Antitumor agent-172 exhibits high affinity to β-catenin with Kd of 82 nM. Antitumor agent-172 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
|
-
- HY-119035
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Inflammation/Immunology
|
|
R-75317 is a specific platelet-activating factor (PAF) antagonist. R-75317 can prevent the decline in creatinine clearance (Ccr) in a rat model of glomerulonephritis induced by the injection of antibodies extracted from rabbits against rat glomerular basement membrane (GBM) antigens, delay the onset of proteinuria, and improve glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. R-75317 may be useful in the study of glomerulonephritis .
|
-
- HY-118156
-
|
|
Others
|
Others
|
|
L-699333 is a 5-lipoxygenase (5-LO) inhibitor belonging to the thieno[2,3,4-cd]indole class. This compound has a 2-ethoxybutyric acid side chain and is a potent inhibitor of the biosynthesis of 5-HPETE and LTB4 produced from human 5-LO, with ICm values of 22 nM, 7 nM, and 3.8 pM for human neutrophils and whole blood, respectively. L-699333 has shown anti-inflammatory and antiasthmatic effects in a variety of animal models, including rat pleurisy models, antigen-induced wheezing models, and awake macaque and sheep asthma models. Its inhibition of 5-LO is highly selective, with higher ICm values or stronger competitive inhibition in FLAP binding assays compared to inhibition of human 15-LO, porcine 12-LO, and ram epididymal cyclooxygenase. The racemic enantiomer 14g of L-699333 is the most potent enantiomer to date, with inhibitory effects similar to those of the known MK-0591, which has been shown in clinical trials to inhibit the biochemical effects of LTB4 biosynthesis in vitro and LTE4 excretion in urine.
|
-
- HY-P10947
-
|
|
Epigenetic Reader Domain
YAP
|
Cancer
|
|
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
|
-
- HY-B1610J
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Sodium citrate buffer, 0.5M, pH 5.0, is a commonly used buffer with main components are citric acid and sodium hydrogen phosphate. Sodium citrate buffer, 0.5M, pH 5.0 is used in heat induced epitope retrieval (HIER) methods to reverse the loss of antigenicity that occurs with some epitopes in formalin-fixed paraffin embedded tissues. Sodium citrate buffer, 0.5M, pH 5.0 is the preferred solution for most antibodies . Sodium citrate buffer, 0.5M, pH 5.0 is used as solution for captisol in animal tumor models .
|
-
- HY-P5396
-
|
|
Amino Acid Decarboxylase
|
Others
|
|
GAD65 (524-543) is a biological active peptide. (This is amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). It is one of the first fragments of this islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. This peptide is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with p524–543 increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells.)
|
-
- HY-163767
-
|
|
β-catenin
|
Inflammation/Immunology
Cancer
|
|
Antitumor agent-171 (Compound 35) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 1.61 μM. Antitumor agent-171 exhibits high affinity to β-catenin with Kd of 0.63 μM. Antitumor agent-171 inhibits the gene expression of axin2 with IC50 of 0.84 μM. Antitumor agent-171 inhibits cell viability of HCT116 with IC50 of 4.39 μM. Antitumor agent-171 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
|
-
- HY-160719
-
|
|
Peptide-Drug Conjugates (PDCs)
|
Inflammation/Immunology
|
|
NHS-activated 2-octynoic acid-BSA is an immunogen used to establish a murine model of primary biliary cholangitis (PBC). NHS-activated 2-octynoic acid-BSA works in conjunction with Complete Freund's Adjuvant (HY-153808) to stimulate the body's immune system, causing the immune system to recognize it as a foreign antigen and trigger an immune response against autologous biliary epithelial cells. This leads to the production of anti-PDC-E2 antibodies, resulting in bile duct damage and inflammation. NHS-activated 2-octynoic acid-BSA is promising for research of primary biliary cholangitis .
|
-
- HY-163691
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Antitumor agent-163 (Compound 3) is a photosensitizer used in Molecular-Targeted Photodynamic Therapy (MT-PDT) targeting carbonic anhydrase IX (CAIX). Antitumor agent-163 inactivates CAIX protein via singlet oxygen under 540 nm wavelength light, without affecting internal standard proteins such as α-tubulin, β-actin, and proliferating cell nuclear antigen (PCNA). Antitumor agent-163 induces cell membrane damage, inhibits cell viability (IC50 is 0.2 and 0.05 μM for A549 and U87MG). Antitumor agent-163 exhibits antitumor efficacy in mouse model .
|
-
- HY-163028
-
|
|
Tim3
|
Cancer
|
|
ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1.
ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research .
|
-
- HY-D1056B3
-
|
LPS, from bacterial (Klebsiella pneumoniae)
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct animal models of sepsis .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
-
- HY-D1056A4
-
|
LPS, from Escherichia coli (O128:B12)
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Lipopolysaccharides, from E. coli O128:B12 (LPS, from Escherichia coli (O128:B12)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O128:B12) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O128:B12 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O128:B12 activate TLR-4 in immune cells, can be used to construct animal models of neonatal brain inflammation, and may influence preterm birth in neonates .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
-
- HY-D1056A2
-
|
LPS, from Escherichia coli (O127:B8)
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Lipopolysaccharides, from E. coli O127:B8 (LPS, from Escherichia coli (O127:B8)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O127:B8) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O127:B8 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O127:B8 activate TLR-4 in immune cells, can induce inflammatory responses and ileal contractility, and can be used to construct intestinal inflammation models .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
-
- HY-D1056
-
|
LPS
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
Cancer
|
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be used to induce cellular inflammation and establish animal models related to inflammation .
It is recommended to prepare a stock solution of ≥2 mg/mL. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
-
- HY-D1056A1
-
|
LPS, from Escherichia coli (O111:B4)
|
Toll-like Receptor (TLR)
|
Inflammation/Immunology
|
Lipopolysaccharides, from E. coli O111:B4 (LPS, from Escherichia coli (O111:B4)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O111:B4) and are classified as S (smooth) type LPS. Lipopolysaccharides (LPS), from E. coli O111:B4 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides (LPS), from E. coli O111:B4 activate TLR-4 in immune cells and can cause significant gastric diseases. Lipopolysaccharides (LPS), from E. coli O111:B4 can be used to induce cellular inflammation and establish animal models related to inflammation .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-NP138
-
|
|
Native Proteins
|
|
NP-OVAL (Ovalbumin) is an immunoconjugate. NP-OVAL (Ovalbumin) is used as a model antigen for the study of multiple myeloma .
|
-
- HY-161549
-
|
|
Biochemical Assay Reagents
|
|
Phosphotyrosine/BSA is an antigen-adjuvant conjugate formed by coupling Phosphotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161553
-
|
|
Biochemical Assay Reagents
|
|
Biotin/KLH is an antigen-adjuvant conjugate that consists of Biotin and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161561
-
|
|
Biochemical Assay Reagents
|
|
PROMETON/OVA is an antigen-adjuvant conjugate formed by the coupling of PROMETON and ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and enhances cross-presentation and the production of antigen-specific T cells.
|
-
- HY-161583
-
|
|
Biochemical Assay Reagents
|
|
Marijuana/BSA is the antigen-adjuvant conjugate of Marijuana and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-161562
-
|
|
Biochemical Assay Reagents
|
|
PROMETON/BSA is an antigen-adjuvant conjugate formed by the coupling of PROMETON with bovine serum albumin (BSA). By coupling the antigen to the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-161529
-
|
|
Biochemical Assay Reagents
|
|
Angiotensin I/BSA is an antigen-adjuvant conjugate of Angiotensin I and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-163556
-
|
|
Biochemical Assay Reagents
|
|
COT/BSA is the antigen-adjuvant conjugate of COT (cyclooctatetraene) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161558
-
|
|
Biochemical Assay Reagents
|
|
Ractopamine/KLH is an antigen-adjuvant conjugate of Ractopamine (HY-113781) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-161533
-
|
|
Biochemical Assay Reagents
|
|
Digoxin/BSA is an antigen-adjuvant conjugate of Digoxin (HY-B1049) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161542
-
|
|
Biochemical Assay Reagents
|
|
Isoniazid/BSA is an antigen-adjuvant conjugate of Isoniazid (HY-B0329) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161540
-
|
|
Biochemical Assay Reagents
|
|
Oxytetracycline/OVA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, it enhances the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or destroy the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-163555
-
|
|
Biochemical Assay Reagents
|
|
BZO/BSA is an antigen-adjuvant conjugate formed by the coupling of BZO (benzodiazepine) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-161555
-
|
|
Biochemical Assay Reagents
|
|
Clenbuterol/KLH is an antigen-adjuvant conjugate of Clenbuterol (HY-B1615) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161554
-
|
|
Biochemical Assay Reagents
|
|
Clenbuterol/BSA is an antigen-adjuvant conjugate of Clenbuterol (HY-B1615) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161566
-
|
|
Biochemical Assay Reagents
|
|
DHT/BSA is an antigen-adjuvant conjugate formed by the coupling of DHT (dihydrotestosterone) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161532
-
|
|
Biochemical Assay Reagents
|
|
Eugenol/OVA is an antigen-adjuvant conjugate formed by the conjugation of Eugenol (HY-N0337) with Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161591
-
|
|
Biochemical Assay Reagents
|
|
SEM/BSA is an antigen-adjuvant conjugate formed by the conjugation of SEM (furanesalin) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161594
-
|
|
Biochemical Assay Reagents
|
|
Furazolidone/BSA is the antigen-adjuvant conjugate of Furazolidone (HY-B1336) and bovine serum albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161530
-
|
|
Biochemical Assay Reagents
|
|
Angiotensin II/BSA is an antigen-adjuvant conjugate formed by the coupling of Angiotensin II with bovine serum albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-163553
-
|
|
Biochemical Assay Reagents
|
|
Metronidazole/BSA is an antigen-adjuvant conjugate of Metronidazole (HY-B0318) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-161557
-
|
|
Biochemical Assay Reagents
|
|
Ractopamine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Ractopamine (HY-113781) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161590
-
|
|
Biochemical Assay Reagents
|
|
AHD/BSA is the antigen-adjuvant conjugate of AHD (furan-2-carboxylic acid) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy the main epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161586
-
|
|
Biochemical Assay Reagents
|
|
Chloramphenicol/BSA is the antigen-adjuvant conjugate formed by the coupling of Chloramphenicol (HY-B0239) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161546
-
|
|
Biochemical Assay Reagents
|
|
Melamine/KLH is an antigen-adjuvant conjugate formed by coupling Melamine (HY-Y1117) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161547
-
|
|
Biochemical Assay Reagents
|
|
Tetracycline/BSA is an antigen-adjuvant conjugate formed by the conjugation of Tetracycline (HY-A0107) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161535
-
|
|
Biochemical Assay Reagents
|
|
Oxytetracycline/BSA is an antigen-adjuvant conjugate formed by the coupling of Oxytetracycline (HY-B0275) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-161580
-
|
|
Biochemical Assay Reagents
|
|
3-Nitrotyrosine/BSA is an antigen-adjuvant conjugate formed by the conjugation of 3-Nitrotyrosine with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it enhances cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161528
-
|
|
Biochemical Assay Reagents
|
|
T3/OVA is an antigen-adjuvant conjugate formed by conjugating T3 (thyroxine) with ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161560
-
|
|
Biochemical Assay Reagents
|
|
Tacrolimus/BSA is the antigen-adjuvant conjugate formed by the conjugation of Tacrolimus (HY-13756) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161541
-
|
|
Biochemical Assay Reagents
|
|
Estradiol/BSA is the antigen-adjuvant conjugate formed by the coupling of Estradiol (HY-B0141) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161589
-
|
|
Biochemical Assay Reagents
|
|
GABA/KLH is an antigen-adjuvant conjugate formed by the coupling of GABA (γ-aminobutyric acid) with keyhole limpet hemocyanin (KLH). By coupling the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161534
-
|
|
Biochemical Assay Reagents
|
|
Sulfadiazine/BSA is an antigen-adjuvant conjugate formed by the conjugation of Sulfadiazine (HY-B0273) with Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161552
-
|
|
Biochemical Assay Reagents
|
|
T3/BSA is an antigen-adjuvant conjugate of T3 (thyroid hormone) and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161588
-
|
|
Biochemical Assay Reagents
|
|
GABA/BSA is an antigen-adjuvant conjugate formed by the coupling of GABA (γ-aminobutyric acid) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161559
-
|
|
Biochemical Assay Reagents
|
|
Sudan I/OVA is an antigen-adjuvant conjugate formed by coupling Sudan I (HY-D0024) with Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the main epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161585
-
|
|
Biochemical Assay Reagents
|
|
Diethylstilbestrol/KLH is an antigen-adjuvant conjugate formed by the coupling of Diethylstilbestrol (HY-14598) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161544
-
|
|
Biochemical Assay Reagents
|
|
Cholyglycine/BSA is a conjugate of Cholyglycine and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-163551
-
|
|
Biochemical Assay Reagents
|
|
The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161545
-
|
|
Biochemical Assay Reagents
|
|
Sudan I/BSA is the antigen-adjuvant conjugate formed by Sudan I (HY-D0024) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161556
-
|
|
Biochemical Assay Reagents
|
|
Alginic acid/KLH is an antigen-adjuvant conjugate formed by the coupling of Alginic acid (HY-W127758) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161526
-
|
|
Biochemical Assay Reagents
|
|
T3/KLH is an antigen-adjuvant conjugate formed by the coupling of T3 (thyroid hormone) with keyhole limpet hemocyanin (KLH). By coupling the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161584
-
|
|
Biochemical Assay Reagents
|
|
Sudan I/KLH is an antigen-adjuvant conjugate formed by the coupling of Sudan I (HY-D0024) with Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161543
-
|
|
Biochemical Assay Reagents
|
|
DHT/KLH is a conjugate of DHT (dihydrotestosterone) and keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt linear epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161587
-
|
|
Biochemical Assay Reagents
|
|
Chloramphenicol/OVA is a conjugate of Chloramphenicol (HY-B0239) and Ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-161581
-
|
|
Biochemical Assay Reagents
|
|
Metronidazole/OVA is a conjugate of Metronidazole (HY-B0318) and Ovalbumin (OVA). By conjugating the antigen with protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt the primary epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-161565
-
|
|
Biochemical Assay Reagents
|
|
Gastrin(1-17)/BSA is an antigen-adjuvant conjugate formed by the coupling of Gastrin(1-17) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-163552
-
|
|
Biochemical Assay Reagents
|
|
Prostaglandin F2a/BSA is an antigen-adjuvant conjugate formed by the conjugation of Prostaglandin F2a with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation as well as the generation of antigen-specific T cells.
|
-
- HY-161563
-
|
|
Biochemical Assay Reagents
|
|
4,4'-Sulfonyldiphenol/BSA is the antigen-adjuvant conjugate of 4,4'-Sulfonyldiphenol (HY-W011927) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
-
- HY-161548
-
|
|
Biochemical Assay Reagents
|
|
Metronidazole/KLH is a conjugate of Metronidazole (HY-B0318) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes and can enhance cross-presentation and the generation of antigen-specific T cells.
|
- HY-161531
-
|
|
Biochemical Assay Reagents
|
|
Diethylstilbestrol/BSA is a conjugate of Diethylstilbestrol (HY-14598) and Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
- HY-163550
-
|
|
Biochemical Assay Reagents
|
|
5-MethylCytosine/BSA is a conjugate of 5-MethylCytosine (HY-W008091) and Bovine Serum Albumin (BSA). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or destroy key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
- HY-161551
-
|
|
Biochemical Assay Reagents
|
|
25-OH Vitamin D3/KLH is an antigen-adjuvant conjugate of 25-OH Vitamin D3 (HY-158285) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
- HY-NP141
-
|
4-Hydroxy-3-nitrophenylacetyl-bovine serum albumin
|
Native Proteins
|
|
NP-BSA (4-Hydroxy-3-nitrophenylacetyl-bovine serum albumin) is an antigen-adjuvant conjugate of 4-Hydroxy-3-nitrophenylacetyl (NP) conjugated to bovine serum albumin (BSA), which is an immune complex. By conjugating antigens to protein adjuvants, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the generation of antigen-specific T cells .
|
- HY-161525
-
|
|
Biochemical Assay Reagents
|
|
1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid linker/BSA is the conjugate of 1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid linker and bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, it enhances the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt key epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
- HY-161527
-
|
|
Biochemical Assay Reagents
|
|
1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid-OVA is a conjugate of 1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid and ovalbumin (OVA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the production of antigen-specific T cells.
|
- HY-B1610J
-
|
|
Buffer Reagents
|
|
Sodium citrate buffer, 0.5M, pH 5.0, is a commonly used buffer with main components are citric acid and sodium hydrogen phosphate. Sodium citrate buffer, 0.5M, pH 5.0 is used in heat induced epitope retrieval (HIER) methods to reverse the loss of antigenicity that occurs with some epitopes in formalin-fixed paraffin embedded tissues. Sodium citrate buffer, 0.5M, pH 5.0 is the preferred solution for most antibodies . Sodium citrate buffer, 0.5M, pH 5.0 is used as solution for captisol in animal tumor models .
|
- HY-D1056B3
-
|
LPS, from bacterial (Klebsiella pneumoniae)
|
Carbohydrates
|
Lipopolysaccharides, from Klebsiella pneumoniae (LPS, from bacterial (Klebsiella pneumoniae)) are lipopolysaccharide endotoxins and TLR4 activators derived from Klebsiella pneumoniae, and are classified as S-type LPS. Lipopolysaccharides, from Klebsiella pneumoniae exhibit a typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from Klebsiella pneumoniae may participate in bacterial immune evasion by inhibiting complement-mediated killing and suppressing the host's secretion of antimicrobial peptides, thereby allowing the bacteria to escape immune defenses. Lipopolysaccharides, from Klebsiella pneumoniae possess high viscosity and resistance to serum-mediated killing, which may lead to sepsis. Lipopolysaccharides, from Klebsiella pneumoniae can be used to construct animal models of sepsis .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
- HY-D1056A4
-
|
LPS, from Escherichia coli (O128:B12)
|
Carbohydrates
|
Lipopolysaccharides, from E. coli O128:B12 (LPS, from Escherichia coli (O128:B12)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O128:B12) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O128:B12 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O128:B12 activate TLR-4 in immune cells, can be used to construct animal models of neonatal brain inflammation, and may influence preterm birth in neonates .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
- HY-D1056A2
-
|
LPS, from Escherichia coli (O127:B8)
|
Carbohydrates
|
Lipopolysaccharides, from E. coli O127:B8 (LPS, from Escherichia coli (O127:B8)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O127:B8) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O127:B8 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O127:B8 activate TLR-4 in immune cells, can induce inflammatory responses and ileal contractility, and can be used to construct intestinal inflammation models .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
- HY-D1056
-
|
LPS
|
Carbohydrates
|
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be used to induce cellular inflammation and establish animal models related to inflammation .
It is recommended to prepare a stock solution of ≥2 mg/mL. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
- HY-D1056A1
-
|
LPS, from Escherichia coli (O111:B4)
|
Carbohydrates
|
Lipopolysaccharides, from E. coli O111:B4 (LPS, from Escherichia coli (O111:B4)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O111:B4) and are classified as S (smooth) type LPS. Lipopolysaccharides (LPS), from E. coli O111:B4 possess the typical three-part structure: O-antigen, R3-type core oligosaccharide, and lipid A. Lipopolysaccharides (LPS), from E. coli O111:B4 activate TLR-4 in immune cells and can cause significant gastric diseases. Lipopolysaccharides (LPS), from E. coli O111:B4 can be used to induce cellular inflammation and establish animal models related to inflammation .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1571
-
|
NP 396
|
Arenavirus
|
Inflammation/Immunology
|
|
Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .
|
-
- HY-P1571A
-
|
NP 396 TFA
|
Arenavirus
|
Inflammation/Immunology
|
|
Nucleoprotein (396-404) TFA is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) TFA is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .
|
-
- HY-P10507
-
|
|
Peptides
|
Cancer
|
|
MART-1 nonamer antigen (LAGIGILTV) is a melanoma antigen that can be recognized by T cells. MART-1 nonamer antigen behaves as a superagonist by in vitro inducing specific T cells with enhanced immunological functions. MART-1 nonamer antigen can be used as a model to design peptides for use in anti-tumour vaccines .
|
-
- HY-P10994
-
|
Eps8(327-335)
|
EGFR
IFNAR
Interleukin Related
TNF Receptor
Complement System
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .
|
-
- HY-P5488
-
|
|
Peptides
|
Others
|
|
BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)
|
-
- HY-P10492
-
|
|
Peptides
|
Others
Metabolic Disease
|
|
Tregitope 289 is a peptide derived from the Fc region of immunoglobulin G (IgG) and is a highly conserved T cell epitope that stimulates the expansion of natural regulatory T cells. Co-delivery of Tregitope 289 with type 1 diabetes (T1D) antigens delays the development of hyperglycemia and reduces the incidence of diabetes in the NOD mouse model. Tregitope 289 can be used to study T1D and other autoimmune diseases .
|
-
- HY-P10947
-
|
|
Epigenetic Reader Domain
YAP
|
Cancer
|
|
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
|
-
- HY-P5396
-
|
|
Amino Acid Decarboxylase
|
Others
|
|
GAD65 (524-543) is a biological active peptide. (This is amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). It is one of the first fragments of this islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. This peptide is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with p524–543 increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells.)
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9932
-
|
ETI 204
|
Bacterial
|
Infection
Cardiovascular Disease
|
|
Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-D1056
-
|
LPS
|
Structural Classification
Polysaccharides
Microorganisms
Classification of Application Fields
Source classification
Inflammation/Immunology
Disease Research Fields
Saccharides
|
Toll-like Receptor (TLR)
|
Lipopolysaccharides, from E. coli O55:B5 (LPS, from Escherichia coli (O55:B5)) are endotoxins and TLR4 activators extracted from Escherichia coli (E. coli O55:B5) and are classified as S (smooth) type LPS. Lipopolysaccharides, from E. coli O55:B5 possess the typical three-part structure: O-antigen, core oligosaccharide, and lipid A. Lipopolysaccharides, from E. coli O55:B5 activate TLR-4 in immune cells, exhibit high pyrogenicity, and demonstrate dose and serotype specificity. Lipopolysaccharides, from E. coli O55:B5 can be used to induce cellular inflammation and establish animal models related to inflammation .
It is recommended to prepare a stock solution of ≥2 mg/mL. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-153808
-
|
|
|
Adjuvant
|
|
Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
